Addiction

MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate

Peer-reviewed publication highlights preclinical findings demonstrating weight loss, lipid normalization, and reduction of compulsive feeding and nicotine-seeking behaviors MIAMI, FL...

QScreen AI Integrates Passive Voice Analysis into Multi-Signal Screening Platform – System Now Reads Physiological, Acoustic, and Behavioral Signals Simultaneously in Real Time

Individual voice baseline established on first encounter, deviation measured on every return visit; no additional hardware required; platform now fully...

QScreen AI Reports Internal Validation Results for Correctional Intake Platform: 100% Sensitivity on Suicide Risk and Withdrawal Detection Across 65 Calibrated Clinical Scenarios

Nine instruments validated against published standards including Columbia C-SSRS, CIWA-Ar, and COWS; paper-only workflow showed materially lower detection rates across...

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory Momentum Seven...

BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum

VANCOUVER, BC / ACCESS Newswire / April 28, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience...

Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty

-- Findings show significant reductions in opioid consumption, healthcare resource utilization, and total medical costs --BRISBANE, Calif., April 27, 2026...

Red Light Holland Highlights U.S. FDA-Authorized Study Supporting Multi-Session Psilocybin Therapy using Filament Health’s Patented PEX010 Botanical Drug Candidate

Study conducted under U.S. FDA Investigational New Drug (IND) authorization by Dr. Anthony Back at the University of WashingtonSecond psilocybin...

error: Content is protected !!